Navtemadlin-Based Therapy Could Drive Change in the Myelofibrosis Treatment Paradigm
John Mascarenhas, MD, discusses navtemadlin’s mechanism of action and its potential to shift the myelofibrosis treatment landscape
Related Articles
Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC
Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.
‘All for one’: City of Hope oncologist focuses on patients after evacuating fires
Ravi Salgia, MD, PhD, and his family were watching coverage of the Los Angeles County fires on their television around 6 p.m. Jan. 7 when…
Understanding the Mechanism and Sensitivity of BCL-2 Inhibitors
John Seymour, MBBS, FRACP, PhD, explains the mechanism of action of BCL-2 inhibitors like venetoclax.
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults
This nonrandomized clinical trial evaluates a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma with…
Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer
The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.
Allo-HSCT Consolidation Appears Beneficial for Older AML Patients
A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.
OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Abstracts
Learn more about and submit your abstract to the AACR Annual Meeting 2025, held April 25-30, 2025, in Chicago, Illinois.
Rewriting the Rules for a Better Future of Cancer Care
Confidence, support, and hard work paved the way for an exceptionally successful career for Edward S. Kim, MD, MBA, who has a cemented mission in…